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Abstract 
Immunotherapy is the new trend in cancer treatment due to the selectivity, long lasting effects, and demonstrated 
improved overall survival and tolerance, when compared to patients treated with conventional chemotherapy. 
Despite these positive results, immunotherapy is still far from becoming the perfect magic bullet to fight cancer, 
largely due to the facts that immunotherapy is not effective in all patients nor in all cancer types. How and when will 
immunotherapy overcome these hurdles? In this review we take a step back to walk side by side with the pioneers of 
immunotherapy in order to understand what steps need to be taken today to make immunotherapy effective across 
all cancers. While early scientists, such as Coley, elicited an unselective but effective response against cancer, the 
search for selectivity pushed immunotherapy to the side in favor of drugs focused on targeting cancer cells. Fortu-
nately, the modern era would revive the importance of the immune system in battling cancer by releasing the brakes 
or checkpoints (anti-CTLA-4 and anti-PD-1/PD-L1) that have been holding the immune system at bay. However, 
there are still many hurdles to overcome before immunotherapy becomes a universal cancer therapy. For example, 
we discuss how the redundant and complex nature of the immune system can impede tumor elimination by teeter 
tottering between different polarization states: one eliciting anti-cancer effects while the other promoting cancer 
growth and invasion. In addition, we highlight the incapacity of the immune system to choose between a fight or 
repair action with respect to tumor growth. Finally we combine these concepts to present a new way to think about 
the immune system and immune tolerance, by introducing two new metaphors, the “push the accelerator” and “repair 
the car” metaphors, to explain the current limitations associated with cancer immunotherapy.
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Introduction
Since war was declared on cancer in 1971, our arsenal of 
drugs against this enemy has steadily increased. The first 
class of drugs developed, conventional chemotherapy 
[1], provided significant benefits for the treatment and 
management of different cancers; however, conventional 
chemotherapy has two intrinsic defects: lack of selec-
tivity [2] and long-term resistance [3]. The subsequent 
development of targeted therapies, including monoclonal 
antibody-based therapies, such as rituximab, overcame 
the lack of selectivity associated with conventional chem-
otherapy by targeting specific proteins involved in can-
cer cell stimulation, proliferation or apoptosis evasion 
[4]. While monoclonal antibody-based strategies have 
significantly increased in clinical practice over the past 
decade, mechanisms of acquired resistance remains a 
hurtle, likely due to genetic and epigenetic instability of 
cancer cells [5]. Thus, despite significant advances made 
in cancer treatment over the past 45 years, we are still far 
from developing therapies capable of effectively ablating 
cancer while avoiding adverse effects on healthy cells and 
loss of efficacy over time.
Starting with Coley’s toxin, followed by Paul Ehrlich’s 
hypothesis of tumor surveillance and contrasted by 
Open Access
*Correspondence:  hmachado@tulane.edu; bruno.sainz@uam.es 
1 Department of Biochemistry, School of Medicine, Autónoma University 
of Madrid, Calle del Arzobispo Morcillo 4, 28029 Madrid, Spain
2 Department of Biochemistry and Molecular Biology, Tulane University 
School of Medicine, 1430 Tulane Ave, #8543, New Orleans, LA 70112, USA
Full list of author information is available at the end of the article
Page 2 of 10D’Errico et al. Clin Trans Med  (2017) 6:3 
Burnet’s immunological tolerance theory [6], the idea 
that the immune system can play a pro- and/or anti-
tumor role has been recognized and debated for years. 
As the immune system is armed to protect against path-
ogens, it has been long postulated that immune cells 
should recognize tumor cells as foreign, and effectively 
eliminate them before spreading to distant organs. This 
concept, today referred to as cancer immunotherapy, 
has the potential to be the magic bullet that investigators 
have been desperately searching for since the early 1900s 
[7].
The last century was a pendulum, swinging between 
big hope and deep disappointment in the immunother-
apy field. Why has our view of immunotherapy shifted 
from promising to disappointing? Can immunotherapy 
be made more effective? In this review we look to the 
past to understand the current problems associated with 
immunotherapy. We present a new way to think about 
the immune system and immune tolerance. In addition to 
the standard “fuel the engine, release the brake” rules of 
immunotherapy, we introduce the “push the accelerator” 
and “repair the car” metaphors to explain part of the cur-
rent limitations associated with cancer immunotherapy.
Immunotherapy: a revolutionary view of cancer treatment
Immunotherapy was born in 1890. Its father, William 
Coley [8], observed that a patient with an inoperable 
sarcoma that suffered a Streptococcus pyogenes infection 
twice obtained complete remission. Based on this obser-
vation, Coley treated approximately 1000 patients with 
inoperable cancers (specially sarcomas) with a mixture 
consisting of killed S. pyogenes and Serratia marcescens, 
achieving a complete remission in 10% of treated patients. 
Compared with actual 5-year survival rates for metastatic 
sarcoma (20%) [9], the effects of Coley’s toxin were prom-
ising and demonstrated that our immune system could 
effectively eradicate tumors with a low rate of adverse 
effects in a subset of patients. While the mechanism of 
action of Coley’s toxin was unknown at the time, Coley’s 
toxin essentially activated tumor-infiltrating leukocytes 
[heterogeneous populations of cells, including varying 
proportions of neutrophils, macrophages, T and B cells, 
and natural killer cells (NK)]. Following administration 
of Coley’s toxin, dendritic cells (DCs), professional anti-
gen presenting cells (APCs), initiate an immune response 
by presenting the captured bacterial antigen to naïve 
CD4+ or CD8+ T cells [10] in lymphoid tissues, which 
results in T cell priming [11] and inflammatory interleu-
kin production [IL-1, IL-2, tumor necrosis factor alpha 
(TNFα,) IL-12] [12, 13]. Clonal T cell expansion triggers 
a humoral immune response by activating B cells, or cel-
lular immunity by activating Th1 effector cells or NK 
cells [14]. Thus, as tumors often display a high degree of 
leukocyte infiltration, it is reasonable that stimulation of 
tumor-infiltrating leukocytes can result in tumor cell tar-
geting and elimination.
The first gauntlet: release the brake
In 1949, some years after Coley’s first experiments, 
Macfarlane Burnet stated, “if in embryonic life expend-
able cells from a genetically distinct race are implanted 
and established, no antibody response should develop 
against the foreign cell antigen when the animal takes on 
independent existence” [6, 15]. Peter Medawar would go 
one step further and propose that the immune system 
becomes tolerant to cancer cells due to the similarities 
that exist with normal healthy cells. In his early experi-
ments, Medawar injected embryonic mouse donor cells 
into mice of a different strain, rendering the recipient 
mice tolerant to future grafts from the donor and not 
third-party strains [16]. These experiments set the ini-
tial groundwork for what would become the concept of 
acquired immunological tolerance. Even if the molecular 
mechanisms explaining Medawar and Burnet’s obser-
vations would not be discovered until 25  years later, 
Medawar and Burnet had already thrown down the first 
gauntlet to modern immunotherapy [16].
Immunological tolerance is a fundamental process, 
the lack of which would result in numerous pathologies 
including autoimmune illnesses. Since Burnet and Meda-
war won the Nobel Prize for their pioneering work in 
this field more than 50 years ago, an enormous amount 
of progress has been made to better understand immune 
tolerance and the numerous redundant mechanisms 
involved in this biological process. In 1959, Joshua Led-
erberg published nine propositions on immunity and 
tolerance [17]. The sixth proposition stated that “the 
immature antibody-forming cell is hypersensitive to an 
antigen–antibody combination: it will be suppressed if 
it encounters the homologous antigen at this time”, high-
lighting that each antibody-producing cell has a single 
specificity [17]. In 1978, Nossal and Pike experimen-
tally demonstrated that bone marrow-derived cells cul-
tured with an antigen became tolerant to the antigen in 
a time-dependent manner, with maximal tolerance being 
achieved only when the antigen was present continuously 
as the cultured bone marrow cells matured [18]. In the 
late 1980’s, Kappler demonstrated central tolerance in 
mice and indicated that tolerance induction may occur in 
the thymus [19]. Goodnow later showed that B cells that 
reactive to “self” antigens are eliminated or silenced in 
order to avoid autoimmunity [20]. And finally, Le Doua-
rin demonstrated that the thymus is not only important 
for central tolerance but it produces cells [i.e. regulatory 
T (Treg) cells] that strongly regulate effector cells, discov-
ering a third dominant form of immune tolerance [21].
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Taken together these results clearly indicated that self-
immune tolerance is maintained and regulated by multi-
ple mechanisms, including similarity with self-antigens, 
regulatory immune cells, a suppressive versus activat-
ing cytokine balance and immune checkpoints. Thus, if 
this process is to be effectively manipulated in order to 
release the brake, we have to stimulate APCs with an 
antigen significantly different from “self” to recruit effec-
tor cells, balance cytokines to obtain a pro-inflammatory 
milieu, and finally, inhibit immune checkpoints to avoid 
tolerance.
Hope dies last
The idea of immune tolerance put forth by Medawar 
and Burnet dampened the hope generated by Coley’s 
experiments that activating the immune system could 
treat cancer. However, in 1953, Foley demonstrated that 
methylcholanthrene-induced tumor cells could produce 
immunogenic antigens in mice, although strain-depend-
ent differences were observed [22]. Nathrath would 
add additional fuel to the fire by showing that the host 
immune system is capable of recognizing new molecu-
lar properties (antigens) displayed by tumor cell as a 
result of the changes accumulating during the transition 
from normal to malignant cells [23]. Interestingly, how-
ever, the greatest hope for immunotherapy would come 
from another illness described in the 1950s, autoimmune 
diseases such as lupus, which clearly confirmed that 
auto-reactive cells can elude self tolerance [24]. Finally, 
towards the later end of the 20th century, immunogenic 
tumor associated antigens were discovered in mice [25] 
and humans [26], resulting from cancer cell genomic 
instability. Unsettling still was the fact that while cancer 
cells could express a multitude of new and unknown anti-
gens as a result of malignant transformation, the immune 
system was not stimulated to target these antigens/cells. 
The problem therefore was no longer the absence of 
immunogenic antigens on cancer cells, but rather under-
standing why our immune system “ignores/tolerates” 
cells harboring these antigens.
In the absence of inflammation, naïve T-cells circulate 
preferentially to secondary lymphoid tissue [27]. During 
an infection, APCs respond to inflammatory cytokines 
(IL-1, TNF-α) [28] and migrate via afferent lymph ves-
sels to lymph nodes where they can interact with naïve 
T-cells. In a similar manner, macrophage or B cells can 
take up and process free antigen in the blood or spleen 
[29]. The interaction of T cell CD28 and DC CD80 (B7-1) 
or CD86 (B7-2) allows for specific T cells to proliferate 
in the paracortex [30] and become competent to receive 
further activation signals from antigen-bearing mac-
rophages and B cells. This process results in the produc-
tion of cytokines, loss of L-selectin (which is involved in 
lymph node entry) and increased expression of adhesion 
molecules like VLA 4 (which facilitates extravasation into 
non-lymphoid tissue) [31]. Macrophages and parenchy-
mal cells produce inflammatory cytokines (IL-1, TNF-α) 
that increase expression of selectins and integrin ligands. 
Ultimately, activated T-cells express adhesion molecules 
that allow them to selectively enter inflamed tissues 
expressing counterpart adhesion molecules. In summary, 
immune cells can present antigens (dendritic cells, mac-
rophages), produce cytokines (macrophage) and inter-
act with cells of the adaptive immune system (B-cells, 
T-cells) in the lymph nodes, resulting in their subse-
quent activation via receptor/ligand interactions. Once 
activated, adaptive immune cells proliferate, alter their 
receptors and adhesion molecules, and finally migrate to 
initiate the destruction of foreign pathogens.
To avoid indiscriminate activation and self-destruction, 
the immune system has developed redundant mecha-
nisms to tolerate self or non-dangerous antigens. Since 
central tolerance is not the underlying mechanisms by 
which cancer cells escape immune targeting, we refer 
the reader to several published reviews detailing the 
biology of central tolerance (Ref. [32, 33]). Peripheral 
tolerance, on the other hand, is the primary mechanism 
utilized by cancer cells to avoid the immune system. In 
the early 1990s, Jenkins and Schwartz demonstrated that 
T-cells need a co-stimulatory signal to fully activate, and 
if T-cells receive only TCR signals they become anergic 
[34]. The co-stimulatory signals must be received from 
APCs [35]: B7-1 (CD80) or B7-2 (CD86) on APCs bind-
ing to CD28 on T-cells is necessary to fully stimulate 
T-cells. While an important step forward in our under-
standing of T-cell regulation, the big discovery was not 
B7-1 or B7-2, but rather the receptor that inhibits the sec-
ond co-stimulatory signal. James Allison, director of the 
UC Berkeley Cancer Research Laboratory, was intrigued 
with a molecule called cytotoxic T-lymphocyte antigen-4 
(CTLA-4) [36], originally discovered in a cDNA library 
derived from activated T-cells. In the late 1990s, Alli-
son and his group began to study how CTLA-4 inhibits 
T-cells and if this inhibition could explain why T-cells do 
not attack cancer cells. They demonstrated that CTLA-
4, a homologue of CD28, bound with higher affinity (at 
least 10-fold) to both B7-1 and B7-2 [37] and inhibited 
CD4+ T-cell activation. Under certain conditions, T-cells 
up-regulate CTLA-4, which binds to B7-1 and B7-2 with 
a higher affinity than CD28, effectively hijacking the sec-
ond co-stimulatory signal that T-cells require for full 
T-cell activation, proliferation, and effector function [38]. 
As a result, T-cells cannot be fully activated and thus 
undergo anergy. Since its discovery, several groups have 
worked diligently towards dissecting the role of CTLA-
4. Studies with CTLA-4−/− mice confirmed its inhibitory 
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function in  vivo. Waterhouse et  al. showed that mice 
lacking CTLA-4 died early on of fatal lymphoproliferative 
disorders [39], demonstrating that CTLA-4 acts as a neg-
ative regulator of T cell activation and is vital for the con-
trol of lymphocyte homeostasis. Based on ever increasing 
data demonstrating a role for CTLA-4 as a negative reg-
ulator of T-cell activation, Allison and colleagues went 
on to show that in  vivo administration of antibodies to 
CTLA-4 promoted the rejection of tumors, including 
pre-established tumors, confirming that CTLA-4 block-
age can allow for, and potentiate, an effective immune 
responses against tumors [40].
The first victory in the new era
These studies and others [41–43] suggested that mono-
clonal antibody-mediated CTLA-4 blockage could rep-
resent an effective anti-cancer therapy. To translate these 
findings to the clinical setting, the Medarex Corpora-
tion generated a series of monoclonal antibodies using a 
unique transgenic mouse (HuMAb), in which the endog-
enous murine immunoglobulin genes had been knocked 
out and replaced with the human loci [44]. Ipilimumab 
showed safety in a phase I study and efficacy in a phase III 
study (ClinicalTrials.gov Identifier: NCT00094653) with 
primary overall survival endpoints. Patients allocated to 
receive ipilimumab had a median overall survival of 10.1 
versus 6.4  months for the control group [hazard ratio 
(HR), 0.68; P ≤  0.003]. Based on the promising results, 
Bristol-Meyer’s Yervoy® (ipilimumab) was approved 
by the US Food and Drug Administration (FDA) and 
the European Medicines Agency (EMA) in 2011 for the 
treatment of metastatic melanoma [38].
While CTLA-4 was the first “checkpoint” inhibitor 
identified, the list of checkpoint immunomodulators 
continues to grow, with inhibitors of the programmed 
cell death protein 1/ligand pathway leading the way. 
Programmed cell death protein 1, also known as PD-1 
and CD279 (cluster of differentiation 279) is a member 
of the CD28 superfamily expressed on activated CD4+ 
and CD8+ T-cells as well as NK and B-cells while pro-
grammed death-ligand 1 (PD-L1), also known as cluster 
of differentiation 274 (CD274) or B7 homolog 1 (B7-
H1), is expressed predominantly on APCs. The main 
role of PD-1 is to act like a stopwatch to limit the activ-
ity of T-cells in the “battle field” during the effector phase 
of T-cell activation in peripheral tissues and the tumor 
microenvironment via the delivery of negative signals 
upon interaction with its two ligands (PD-L1 or PD-L2). 
PD-L1 and PD-L2 compete for PD-1 [45] and upon bind-
ing both inhibit T cell proliferation, cytokine production 
and cell adhesion [46], although some contradictory data 
have suggested a costimulatory function [47]. T-cells 
begin to express PD-1 when activated and its expression 
increase over time [48, 49], while PD-L1 is expressed on 
APCs present in the inflamed tissue. PD-1 is also highly 
expressed on Treg cells, where it may enhance their pro-
liferation in the presence of ligand [50]. The expression 
on Treg cells also highlights the role PD-1 plays in regu-
lating the induction and maintenance of peripheral tol-
erance and protection from autoimmune attack [51]. 
Our current understanding of the PD-1/PD-L1 pathway 
shows that engagement of PD-1 and PD-L1 leads to inac-
tivation of effector T-cell molecules such as Zap70 to 
inhibit T-cell proliferation, thus limiting the inflamma-
tory damage in inflamed tissues [52]. For example, dur-
ing chronic infections the PD-1/PD-L1 pathway leads to 
anergy [53]. It appears as though several cancers, includ-
ing lung, ovarian and colon carcinomas as well as mela-
nomas, have evolved to over express PD-L1 [54]. Thus, 
chronic tumor associated antigen exposure in cancer 
can lead to high levels of PD-1 expression on T-cells, 
which can interact with PD-L1 expressed on cancer cells, 
inhibiting T-cell activation and perhaps inducing a state 
of anergy in immune cells present in the tumor. Block-
ing the PD-1/PD-L1 pathway can revert this condition, 
promoting cancer cell elimination by activated T-cells. 
In the past 5  years, Bristol-Myers Squibb has produced 
a fully humanized antibody against PD-1 named Opdivo 
(Nivolumab), which obtained FDA accelerated approval 
in 2014 [55] based on the “Study of Nivolumab (BMS-
936558) Compared With Dacarbazine in Untreated, 
Unresectable, or Metastatic Melanoma”.
Today many check-point inhibitors are used by oncolo-
gist to achieve significant increases in survival rates (e.g. 
1- and 2-year survival rates of 62 and 43%, respectively 
for melanoma or 1- and 2-year survival rates of 42 and 
23%, respectively for lung cancer) and/or to achieve a 
durable partial or complete response in cancer patients 
(e.g. 31% for melanoma patients) [56, 57]. Table  1 sum-
marizes the current FDA- and EMA-approved immune 
checkpoint inhibitors. Clinical studies have also inves-
tigated the efficacy of combination therapies using anti-
PD-1/PD-L1 therapies together with other checkpoint 
inhibitors, such as the anti-CTLA4 treatment ipili-
mumab. The combination of nivolumab and ipilimumab 
increased overall survival in patients with untreated 
melanoma. The median progression-free survival was 
11.5  months (95% confidence interval [CI], 8.9–16.7) 
with nivolumab plus ipilimumab, as compared with 
2.9  months (95% CI, 2.8–3.4) with ipilimumab (hazard 
ratio for death or disease progression, 0.42; 99.5% CI, 
0.31–0.57; P < 0.001), and 6.9 months (95% CI, 4.3–9.5) 
with nivolumab (hazard ratio for the comparison with 
ipilimumab, 0.57; 99.5% CI, 0.43–0.76; P < 0.001) [58]. It 
is important to stress that even if combination therapy 
allows us to obtain better results and improved medium 
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overall survival, it is still far from becoming the perfect 
therapy. The current underlying problem with immune 
checkpoint inhibitors is that if there are no T-cells in the 
tumor border then there are no effector cells capable of 
eliminating the tumor cells. Therefore, even if we release 
the brake we cannot obtain clinically relevant results. 
Thus, the next strategy lies in “fueling the engine”, that is 
allowing T-cells to reach the tumor border.
Fueling the engine
As stated above, immune checkpoints inhibitors are 
only effective if tumors are infiltrated with T-cells. 
Therefore, if a tumor lacks infiltrated T-cells, immune 
checkpoint inhibitors are essentially ineffective. Cancer 
vaccines have been extensively investigated as a strat-
egy to induce T-cell infiltration in the tumor—“fuel the 
engine”. Currently, however, Sipileucel is the only “cellular 
immunotherapy” (i.e. vaccine therapy) approved by the 
FDA. Sipileucel consists of autologous peripheral blood 
mononuclear cells (PBMCs), obtained by leukapheresis 
and cultured with a prostatic acid phosphatase linked 
to granulocyte–macrophage colony-stimulating factor 
(GM-CSF) [59]. Results from the 9902B study in patients 
with prostate cancer demonstrated an overall survival of 
25.8 months for patients receiving Sipileucel compared to 
21.7 months for patients who received the control treat-
ment [59].
While Sipileucel demonstrates the clear benefit of 
“fueling the engine”, the use of cancer vaccines in other 
tumor types is still in the experimental stages. For exam-
ple, Kleponis et al. developed a GM-CSF-secreting pan-
creatic cancer vaccine (GVAX) that provided maturation 
signals to APCs at the local vaccine site. Stimulated APCs 
processed tumor antigens and presented them to T-effec-
tor cells, allowing T-cells to infiltrate the tumor [60]. 
The authors went on to show that PD-L1 expression was 
induced in the infiltrating cells (T-cells). This study dem-
onstrated that vaccine-based therapies may have ade-
quately primed pancreatic cancer for anti-PD-1/PD-L1 
treatments, highlighting that this typically T-cell-effector 
poor/Treg-rich tumor [61] could be potentially treated 
with PD-1/PD-L1 inhibitors. Thus, cancer vaccine-based 
immunotherapy may overcome the resistance of certain 
cancers to immune checkpoint inhibitors, while immune 
checkpoint inhibitors may enhance the efficacy of the 
cancer-vaccine therapies. The goal of a combination 
strategy is to combine the strength of each immunother-
apy approach, with cancer vaccines functioning to “fuel 
the engine” and immune checkpoint inhibitors working 
to “release the brake”.
Perplexing is the fact that PD-1 and CTLA-4 check-
point inhibitors, even when helped by cancer vaccines, 
are not effective against all cancer types, nor do they 
work in every patient with the same cancer. Perhaps 
other immune cell types are negatively affecting can-
cer immunotherapy? The explanation we put forward to 
explain this dilemma is that in some cancers we have the 
machinery (the car) on a downhill slope, so if we release 
the brake (immune checkpoint inhibitors) the car can 
move. In contrast, when we are on an uphill slope or on a 
plain field, releasing the brake simply does not move the 
car. For such scenarios, we have to release the brake and 
push the accelerator.
Looking deep inside the immune system we can find 
a dynamic and complex environment of cells that are 
different in type, size, complexity, markers and func-
tion. Even the same cell can exist in two (or more) dif-
ferent polarized states. For example, macrophages can 
switch between a pro-inflammatory (classically acti-
vated) and a reparative (alternatively activated) state 
[62]. T-cells can be stimulated into T effector cells or 
Tregs cells, each of which can have a very distinct role 
within a tumor [63]. Thus, we need to take a step back 
and understand why, when and how a cell (i.e. mac-
rophage, T-cell, etc.) can switch from a classically acti-
vated (inflammatory macrophage or T effector cell) 
to an alternatively activated (pro-tumorigenic mac-
rophage or Treg) state and what mediates this change. 
Answering these questions may provide the key to push 
the accelerator.
Table 1 Summary of immune therapies in clinical use
Immune therapy Target Stage Cancer type Ref.
Ipilimumab CTLA-4 Clinical use Advanced melanoma 107
Nivolumab PD-1 Clinical use Melanoma
Renal cancer
NSLC
108
109
110
Pembrolizumab PD-1 Clinical use Melanoma 111
Atezolizumab PD-L1 Clinical use NSLC
Clear renal cancer bladder cancer
112
113
Sipileucel Peripheral blood  
mononuclear cells
Clinical use Prostate cancer 114
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Immune cells: Dr. Jekyll and Mr. Hide
The immune system is comprised of many cells, includ-
ing but not limited to dendritic cells, mast cells, mac-
rophages, neutrophils and lymphocytes. In addition, and 
to complicate the matter even more, immune cells are 
extremely plastic and each cell type can differentiate into 
at least two forms depending on their environment and 
the paracrine signals they receive (reviewed in [64–66]). 
Lymphocytes can differentiate into many subsets. Apart 
from B and T cells, T lymphocytes can differentiate into 
CD8+ or CD4+ T cells, the latter of which can in turn 
differentiate into Treg and Thelper cells [67]. DCs that pre-
sent captured antigens to naïve T-cells, have two major 
subsets: myeloid (i.e. conventional DC or immunogenic 
DC) and plasmacytoid form (or tolerogenic DC) [68]. As 
described above, macrophages can exist in at least two 
forms [69], and in the context of a tumor, macrophages 
and neutrophils can differentiate into tumor-associ-
ated macrophages (TAMs) or neutrophils (TANs) [70], 
respectively.
The interest in the different states of immune cells, 
particularly within the tumor, stems from the different 
biological affects these cells produce depending on their 
state, polarization or differentiation (Fig.  1). For exam-
ple, human DCs can exist as immunogenic or tolerogenic 
DCs [71], with immunogenic DCs functioning primar-
ily to stimulate a Thelper [72] response while tolerogenic 
DCs function primarily to stimulate a Treg response 
[73]. Moreover, the ratio of different DCs depends on 
the cytokine milieu. In vitro studies clearly demonstrate 
that GM-CSF, interferon alpha (IFNα), or IL-15 can 
induce the differentiation of inflammatory DCs while 
IL-10, vitamin A or D3, or immunosuppressive drugs 
such as cyclosporine A induce tolerogenic DCs through 
E-cadherin mediated signaling [74, 75]. Thus, depending 
on the cytokine milieu, DCs can elicit a strong immune 
response or a tolerogenic state.
Macrophages represent another important cell type 
that play a pivotal role in activating and shaping the 
immune response, and similar to DCs, a dichotomy has 
been proposed for macrophage activation: classically or 
alternatively activated [76, 77]. IFNα, LPS or inflamma-
tory cytokines can induce classical activation while IL-4, 
IL-13, TGF-β and reparatory signals can induce alterna-
tive activation of macrophages. In the last decade, if mac-
rophages have gone from a negligible player in tumor 
progression to a pivotal modulator of tumor growth and 
metastasis, it is due to the identification of TAMs. There 
is now solid and continuously growing evidence to show 
that TAMs actively promote all aspects of tumor growth 
and development including promotion of angiogenesis, 
matrix remodeling and suppression of adaptive immunity 
[78]. Recent studies also show that TAMs share many 
characteristics with alternatively activated macrophages 
such as (1) activation of the arginase pathway, implicated 
in arginine metabolism; (2) promotion of cell repair and 
proliferation in strong opposition with the NOS pathway 
that promote cells killing [79]; (3) production of IL-10 
and vascular endothelial growth factor (VEGF) over 
other factors promoting cell survival [80]; (4) produc-
tion of matrix metalloproteinases (MMPs), implicated in 
cancer initiation and metastasis [81, 82]; (5) activation of 
NFκB and STAT3 signaling, enhancing tumor progres-
sion by directly communicating with cancer stem cells 
(CSCs) [62], and (6) activation of STAT6, which possess 
potent inhibitory activity of T-cell activity [83].
Fig. 1 The two faces of immune cells: The Dr. Jekyll and Mr. Hide 
concept. Immune cells, including dendritic cells (DCs), T-cells, mac-
rophages and neutrophils, are extremely plastic and can assume dif-
ferent roles/functions depending on factors encountered at the site 
of infection or within the tumor microenvironment. When stimulated 
by factors such as TGF-ß or when in contact with apoptotic cells, 
immune cells become pro-tumorigenic (left side) and differentiate/
polarize towards tolerogenic DCs (Tol-DC), Treg cells, tumor-associated 
macrophages (TAMs) or tumor-associated neutrophils (TANs). In 
contrast, when stimulated by pro-inflammatory cytokines, such as 
IFNs, IL-1 or IL-12, immune cells become anti-tumorigenic (right side) 
and differentiate/polarize towards immunogenic DCs (immuno-
DC), T effector cells, activated pro-inflammatory macrophages or 
neutrophils
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T-cells, the soldiers of the immune system, have a 
fundamental role in immune surveillance, and even for 
these cells a dichotomy exists: a T-cell can defend the 
host from cancer while aiding tumor growth. Zhang 
et al. showed that ovarian carcinoma patients with high 
tumor infiltrating lymphocytes had improved 5-year 
survival rates compared to patients with low tumor 
infiltrating lymphocytes [84]; however, in other can-
cers, such as renal cancer, high tumor infiltrating lym-
phocytes translated into worse prognosis [85]. These 
clear opposing observations are now explained by 
differences in the type of infiltrating T-cells: Treg ver-
sus T effectors cells (TCD8+). Treg cells, a subgroup of 
T-cells expressing CD4 and CD25, regulate activation 
of other T-cells and are necessary to maintain periph-
eral tolerance to self-antigens. We have now come to 
understand that increased numbers of Treg cells present 
in the tumor can have a negative prognostic impact. 
For example, Sato et  al. showed that a high TCD8+/
Treg cell ratio translated into better overall survival 
while the opposite was seen for a high Treg/TCD8+ 
ratio [86]. Likewise, Li et al. demonstrated that the effi-
ciency and percent depletion of Treg cells from a tumor 
can improve cancer outcome [67, 87]. Specifically, 
they show that in Foxp3.LuciDTR-4 mice, which show 
90–95% Treg depletion, large established tumors com-
pletely regressed, unlike anti-CD25 antibody-mediated 
Treg elimination, which is less efficient (approximately 
70%). Thus, high-level depletion of Treg cells is neces-
sary for tumor regression.
Like a coin, immune cells have two faces, one with a 
strong potential to fight cancer and the other (the oppo-
site one) strongly promoting cancer development and 
immune system escape. This Dr. Jekyll and Mr. Hide con-
cept has been re-coined the “corrupted policemen” con-
cept by Bonavita et al. in order to stress the fact that those 
cells born to protect the host can become corrupt and 
turn against it to favor cancer growth [88]. This switch 
is complex and partly mediated by cytokines: inflamma-
tory cytokines promoting immune system cells to show 
their anti-cancer face while anti-inflammatory cytokines 
promote the pro-cancer side to dominate. But cytokines 
are only mediators. More important are the stimuli that 
induce immune host cells to convert into either cancer 
allies (pro-tumor macrophages, Treg cells, or tolerogenic 
DC) or cancer enemies (inflammatory macrophage, 
CD8+ T-cells, Thelper cells or immunogenic DC) (Fig. 1). 
If we discover which mechanism(s) induce the inflam-
matory anti-cancer response and which ones induce the 
pro-cancer response, in theory we could pharmacologi-
cally change the face of the coin, favoring an anti-cancer 
response.
To fight or to repair? That is the question
The first problem that oncoimmunotherapists faced 
was immune tolerance. Currently, a more challeng-
ing dilemma lies in the ability of the immune system to 
balance itself between two opposing actions: “fight” the 
enemy or “repair the damage”. A successful immune 
response can be accompanied by extensive tissue damage 
[89]. Fortunately, the immune system has the capacity to 
repair the resulting damage via Treg cells, macrophages 
and anti-inflammatory cytokines that send a repair mes-
sage to the site of damage. In the context of cancer, how-
ever, the wrong choice can have detrimental effects on 
tumor eradication, as alluded to above. Numerous stud-
ies have shown that tumor growth and even post treat-
ment tumor cell death can be perceived by the immune 
system as a repair signal, initiating a wound healing 
response that can favor sustained tumor growth and even 
tumor chemoresistance via immune cell secreted fac-
tors (reviewed in [90, 91]). Dissecting how the immune 
system senses and responds to damage will improve our 
efforts of inhibiting the immune system from favoring 
tumor growth over tumor destruction.
After immune system activation, the battlefield is 
replete with damaged cells, the majority being apop-
totic cells (e.g. bacteria, neutrophils, epithelial cells). It is 
therefore logical to think that these cells could regulate 
the immune system or represent the signal that promotes 
a repair response. Although conventional and targeted 
therapies often aim to induce apoptosis, these strategies 
may themselves be carcinogenic [92].
The relation between cancer, immune cells and dead/
apoptotic cells has gained increased attention over the 
past decade. Apoptosis obtained through activation of 
caspases or mitochondrial chain dysfunction was histori-
cally declared as non-immunogenic, while necrotic death 
accompanied by the release of proteins, lipids and other 
cellular debris from cells has been widely considered as 
strongly immunogenic [93, 94]. Chemotherapy-mediated 
cell death was accepted as an apoptosis-mediated pro-
cess, inducing an immunosuppressive milieu of cytokines 
[95], but studies show that depending on the agent used 
and the degree of cell death induced, chemotherapy can 
also induce necrotic cells [96]. Moreover, other studies 
have shown that classically-induced apoptotic cells can 
profoundly affect the immune system [97], and the idea 
that chemotherapy-induced apoptosis is non-immuno-
genic may be overstated [98–100].
In cancer, there appears to be a ying-yang scenario 
with respect to the presence of dead cells and method 
of cell death induction. The presence of apoptotic cells 
can be sensed and translated into a “need to repair” 
action, allowing Treg/Th2 stimulation through cytokine 
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expression (IL-10, IL-13) [100, 101]. On the other hand, 
necrotic cells or highly variable tumor associated anti-
gens can be sensed and translated into a “need to fight” 
action, allowing T-CD4+ stimulation thought inflamma-
tory cytokine expression (TNF-α, IL-1, etc.) [93]. Wil-
liams et al. showed that DCs exposed to apoptotic Jurkat 
cells or apoptotic primary T-cells failed to maturate and 
were unable to support CD4+ allogeneic T-cell prolifera-
tion, as compared to DCs exposed to lipopolysaccharide 
(LPS) or necrotic cells [102]. Conversely, phosphatidyl-
serine exposed on apoptotic epithelial cells suppressed 
IFN-β production by dendritic cells via inhibitory signal-
ling mediated by the cell-surface glycoprotein CD300a 
and thus suppressed Treg cell proliferation [103]. More-
over, Kleinclauss et al. in 2006 demonstrated that apop-
totic cells induce CD4+ T-cells to express CD25+ (a 
marker of Treg cells) inducing a state of tolerance [104]. 
Taken together, these studies demonstrate that the 
immune system can sense the type of danger and acti-
vate a specific action. In our laboratory we have discov-
ered that apoptotic pancreatic tumor cells, as opposed to 
necrotic or live cells, can strongly induce immune system 
suppression or a pro-Th2 state, promoting repair signals 
that favor pancreatic tumor growth and chemoresistance 
(unpublished data). Our observations are in line with data 
published by Wu et al. where they show that intravenous 
administration of donor apoptotic splenocytes promotes 
the generation of tolerogenic DCs and the expansion of 
Treg cells in the pancreas; in vivo clearance of either DCs 
or Treg cells abrogated immune tolerance induction [105]. 
Thus, in pancreatic cancer where chemotherapies such 
as gemcitabine induce tumor cell apoptosis, an immune 
response that favors tumor growth may be activated.
Conclusion
The field of cancer immunotherapy has been driven by 
scientists such as William Coley whose important results 
set the foundation for modern day immunotherapy, as 
well as by scientists who while opposed the concept of 
immunotherapy made pinnacle discoveries that favored 
the evolution of immunotherapy into one of the most 
promising techniques in place today to battle cancer. The 
scientific community is convinced that immunotherapy 
is only a step away from becoming the magic bullet to 
defeat cancer. While the future looks promising, there are 
still many hurdles that need to be overcome.
We now have the capacity to “fuel the engine” by using 
vaccine strategies to accumulate effector T-cells at the 
tumor border, and “release the brake” to allow T-cells to 
fight the cancer by inhibiting immune system checkpoints. 
This strategy allows us to fight cancer when the battlefield 
is downhill or when the tumor entity itself is “immuno-
genic” due to (1) profound differences in tumor associated 
antigens between normal cells and tumor cells or (2) the 
presence of immunogenic necrotic cells. This strategy, how-
ever, is ineffective when the battlefield is plain or uphill, or 
when the tumor itself promotes a “need to repair” response 
due to chemotherapy-induced apoptosis or other unknown 
factors. Thus, when faced with this scenario, an approach to 
ensure that the immune system senses the cancer as danger 
in order to promote a “need to fight” over a “need to repair” 
response is essential. Consequently, the “push the accelera-
tor” component of the universal magic bullet is still lacking. 
This action may possibly be achieved by educating APCs 
(DCs and macrophages) to sense every cancer as “danger-
ous”, ensuring an anti-tumor immune response in all cases. 
Moreover, understanding that certain immune cells (e.g. 
macrophages) can shift the immune response in one direc-
tion over another, combination therapies may be necessary 
to transiently eliminate other immune cells. Ultimately, 
the goal is to unmask those factors that promote a “need 
to repair” response while at the same time enhancing those 
factors that are sensed as a danger signal by the immune 
system. Only then will immunotherapy truly become the 
magic bullet for cancer treatment.
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